# Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy

Study · id `cardio:ct-nct07746882` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07746882](<https://clinicaltrials.gov/study/NCT07746882>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07746882

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 680 participants.

## Technical summary

Registry record NCT07746882. Randomized; double masking; primary purpose treatment. Start 2026-08-15 (anticipated); primary completion 2028-08-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 680 participants (planned count; ClinicalTrials.gov record NCT07746882, source copy `cardio:ctgov-nct07746882-2026-08-05`, retrieved 2026-10-26)
- Planned start: 2026-08-15 (anticipated) (ClinicalTrials.gov record NCT07746882, source copy `cardio:ctgov-nct07746882-2026-08-05`, retrieved 2026-10-26)
- Primary completion: 2028-08-31 (anticipated) (ClinicalTrials.gov record NCT07746882, source copy `cardio:ctgov-nct07746882-2026-08-05`, retrieved 2026-10-26)
- Completion: 2028-11-30 (anticipated) (ClinicalTrials.gov record NCT07746882, source copy `cardio:ctgov-nct07746882-2026-08-05`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07746882-2026-08-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy
- Condition: Stroke
- Condition: Acute Ischemic Stroke
- Intervention (Drug): Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran
- Intervention (Drug): Aspirin
- Lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine (`cardio:org-second-affiliated-hospital-zhejiang-university-school-of-bfd3ac`)

## Provenance

Content hash: e220748d4958ede3e433ab9cda81157b67ef8ab74838d2eb11a7484eaef9c849
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
